Betrixaban activates cGAS and ERVs to promote dual nucleic-sensing antiviral immunity - PubMed
3 hours ago
- #cGAS-STING
- #Antiviral Immunity
- #Betrixaban
- Betrixaban (BT), an FDA-approved oral Factor Xa inhibitor, induces a robust antiviral state through dual innate immune pathways.
- BT directly binds and activates the DNA sensor cGAS, promoting cGAMP production.
- BT inhibits histone deacetylases (HDACs), leading to chromatin de-repression of endogenous retroviruses (ERVs) and production of immunostimulatory dsRNA.
- The combined activation of cGAS and ERV pathways triggers strong type I interferon responses.
- BT provides broad-spectrum antiviral protection against both RNA and DNA viruses in vitro and in vivo.
- The study suggests repurposing BT as an orally broad-spectrum antiviral.